Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 955-731-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No data for the substance "Sophorolipids: fermentation products of glucose and fatty acids, C18 (unsaturated), glycerol esters with yeast Starmerella bombicola, hydrolysed" on toxicity to reproduction is available. Therefore, data from a suitable read-across partner, was used to assess the toxicitiy to reproduction for the target substance. For details and justification of read-across please refer to the report attached in section 13 of IUCLID.
No effects on reproductive toxicity were observed in an OECD 421. The No Observed Adverse Effects Level (NOAEL) of the source substance for reproductive and developmental toxicity including satellite group animals was considered to be 500 mg/kg bw/day (for active ingredient) for both parental animals and offspring, this being the highest dose investigated. Dose levels have been selected based on information from a previous repeated dose toxicity study (Rossiello 2018, OECD 407, LOAEL 1000 mg/kg/day).
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Remarks:
- OECD 421
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- For details and justification of read-across please refer to the report attached in section 13 of IUCLID.
- Reason / purpose for cross-reference:
- read-across source
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No relevance was attributed to the hairloss and/or staining observed in one lowdose female, one mid-dose female of the main group or in one high dose male and two high dose females of the satellite groups. These signs were considered incidental. Since the hairloss was observed at fore- and hindlimbs this was caused by licking.
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Parental males
Thyroxine showed a statistically significant increase in a number of males dosed at 500 mg/kg/day (mean group value was 12 % above controls). Due to the minimal severity and the absence of other related changes, this finding was considered of no toxicological relevance.
Offspring - Day 14 post partum
A decrease of Thyroid Stimulating Hormone was recorded in some male pups of all treated groups. Compared with controls, changes were 21 % to 31 %, with no dose-relation. Due to the absence of dose-relation and of other related changes, this finding was not considered to be treatment-related. - Endocrine findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Parental animals
No treatment-related changes were noted, following histopathology evaluation. Seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and to the integrity of the various cell types within the different stages. As regular layering in the germinal epithelium was noted, there was no treatment-related effect on the spermatogenic cycle. All reported changes were considered spontaneous and incidental, having a comparable incidence in control and treated groups, and/or are characteristically seen in untreated
Sprague Dawley SD rats of the same age.
Satellite groups
No treatment-related changeswere noted, following histopathology evaluation of bone marrow, spleen and thymus. All reported changes were considered spontaneous and incidental, having a comparable incidence in control and treated groups, and/or are characteristically seen in untreated Sprague Dawley SD rats of the same age. - Histopathological findings: neoplastic:
- no effects observed
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Remarks:
- in terms of test item corrected for solid content (47.2%)
- Sex:
- female
- Basis for effect level:
- other: no adverse effects observed at highest dose level
- Key result
- Critical effects observed:
- no
- Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- Pup no.12 of dam X0780031 of the low dose group was found moribund and with no milk in the stomach on Day 4 post partum. This pup was selected for culling. No abnormalities were found at necropsy.
No signs related to treatment were seen in the remaining pups. - Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A decrease of Thyroid Stimulating Hormone was recorded in some male pups of all treated groups. Compared with controls, changes were 21 % to 31 %, with no dose-relation. Due to the absence of dose-relation and of other related histopathological changes, this finding was not considered to be treatment-related.
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Thyroid weight in treated pups was comparable to controls.
- Gross pathological findings:
- no effects observed
- Histopathological findings:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 500 mg/kg bw/day
- Based on:
- test mat.
- Remarks:
- in terms of test item corrected for solid content (47.2%)
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed at highest dose level
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- Under the experimental conditions of this study, the No Observed Adverse Effects Level (NOAEL) for reproductive and developmental toxicity including satellite group animals was considered to be 500 mg/kg/day (for active ingredient) for both parental animals and offspring, this being the highest dose investigated.
- Executive summary:
In a reproduction/developmental toxicity screening test according to OECD guideline 421, the test substance “Sophorolipids: fermentation products of glucose and fatty acids, C18-unsatd., esters with glycerol with yeast Candida bombicola, partially hydrolysed” (47.2%) was orally administered to Sprague Dawley rats (10/sex/dose) at doses of 1, 100, 300 and 500 mg/kg bw/day. Dose levels have been selected based on information from a previous repeated dose toxicity study (Rossiello 2018, OECD 407)
Males of groups 1 to 4 were treated for 2 weeks prior to pairing and during pairing with females until the day before necropsy, for a total of 29 or 30 days. Females of groups 1 to 4 were treated for 2 weeks prior to pairing, during pairing and throughout the gestation and lactation periods until Day 13 post partum. The following investigations were performed in all groups: mortality check, clinical signs, bodyweight, bodyweight gain, food consumption and mating performance and thyroid hormone determination only for parental males and pups at day 14 post partum (1 pup/sex/group), litter data, macroscopic observations, organ weights. Clinical signs, anogenital distance, external and internal examination of pups at necropsy were also recorded. The histopathological examination was performed only on control and high dose group animals and included identification of the stages of the spermatogenic cycle. In addition, 2 satellite groups (control and high dose) were included for specific histopathology investigations (spleen, thymus and bone marrow) and sacrificed after 4 weeks of treatment.
For parental main groups animals, no adverse effects were found on oestrous cycle, copulation, fertility, delivery or lactation gestation length, number of corpora lutea or implantation sites. No adverse effects were found in anogenital distance, pup sex ratios, pup weight, pup viability and no treatment related findings were noted at necropsy. Thyroid weights of the parental animals and of pups on Day 14 post partum were comparable to the control group. Macroscopic observation and organ weight were unaffected by treatment. No treatment related changes were described following histopathology evaluation in main and satellite groups, including spermatogenic cycle. Slight changes noted in thyroid hormone levels were considered not related to treatment. The histopathological examination performed in satellite group animals did not show any changes related to treatment.
The No Observed Adverse Effects Level (NOAEL) for reproductive and developmental toxicity including satellite group animals was considered to be 500 mg/kg/day (for active ingredient) for both parental animals and offspring, this being the highest dose investigated.
This information is used in a read-across approach in the assessment of the target substance. For justification of read-across please refer to the attached read-across report (see IUCLID section 13).
Reference
No mortality occurred during the study. One control female (no. X0780015) was proved not pregnant at necropsy and the mid-dose female no. X0780053 had total litter loss on Day 0 post partum.
The number of females with live pups on Day 14 post partum was: 9 in the control, 10 in the low dose (100 mg/kg/day), 9 in the mid-dose (300 mg/kg/day) and 10 in the high dose group (500 mg/kg/day).
No signs were recorded in males of the main groups during the study. No relevance was attributed to the hairloss and/or staining observed in one low dose female, one mid-dose female of the main group or in one high dose male and two high dose females of the satellite groups. These signs were considered incidental.
No differences of toxicological relevance were observed in body weight or body weight gain between the control and treated animals.
The food consumption was comparable between groups.
Parental males
Thyroxine showed a statistically significant increase in a number of males dosed at 500 mg/kg/day (mean group value was 12% above controls). Due to the minimal severity and the absence of other related changes, this finding was considered of no toxicological relevance.
Pups - Day 14 post partum.
A decrease of Thyroid Stimulating Hormone was recorded in some male pups of all treated groups. Compared with controls, changes were 21 % to 31 %, with no dose-relation. Due to the absence of dose-relation and of other related changes, this finding was not considered to be treatment-related.
Oestrous cycle, reproductive parameters, pairing combination and mating performance
Oestrous cycle and reproductive parameters (pre-coital intervals, copulatory and fertility indices) were similar in treated and control groups. All females were pregnant except for one control female (animal no. X0780015).
Implantation sites, pre-implantation loss data, pre-natal loss data and gestation length of females
Gestation periods were similar between treated and control group females. All pregnant females gave birth on Day 22 post coitum (mean value). Corpora lutea, implantation sites, total litter size, pre-implantation loss and pre-natal loss (percentage) were similar in control and treated groups.
Litter data at birth, on Day 1 and on Day 4 post partum (before culling), on Day 13 (after culling) post partum and sex ratio: No differences in litter data were seen between control and treated groups.
Sex ratios (calculated as a percentage of males) at birth and on Days 4 and 14 post partum did not show differences between groups.
Anogenital distance
Anogenital distance (normalised for the cube root of the pup weight collected on Day 1 post partum) was unaffected by treatment.
Clinical signs of pups and nipple observations
Pup no. 12 of dam X0780031 of the low dose group was found moribund and with no milk in the stomach on Day 4 post partum. This pup was selected for culling. No abnormalities were found at necropsy. No signs related to treatment were seen in the remaining pups.
No nipples were present in any male pup, when observed on Day 13 post partum. Necropsy findings in decedent pups, culled pups and in pups sacrificed on Day 14 post partum.
No treatment-related findings were described. Pups thyroid weight on Day 14 post partum. Thyroid weight in treated pups was comparable to controls.
Terminal body weight of treated animals of the three main groups (Groups 2, 3 and 4), as well as the high dose satellite group (Group 6) was comparable to the concurrent control group (Group 1 or 5).
No relevant changes were observed in absolute and relative organ weight in all treatment groups of both sexes, when compared to the concurrent control data. All organ weight variations between control and treated animals were considered to be within the physiological range of Sprague Dawley SD rats of this age.
Macroscopic observations
No treatment-related changes were noted, following gross pathology examination in either main or satellite groups. All observed changes were considered spontaneous and incidental, having a comparable incidence in control and treated groups and/or are characteristically seen in untreated Sprague Dawley SD rats of the same age.
Microscopic observations
Parental animals
No treatment-related changes were noted, following histopathology evaluation. Seminiferous tubules were evaluated with respect to their stage in the spermatogenic cycle and to the integrity of the various cell types within the different stages. As regular layering in the germinal epithelium was noted, there was no treatment-related effect on the spermatogenic cycle.
All reported changes were considered spontaneous and incidental, having a comparable incidence in control and treated groups, and/or are characteristically seen in untreated Sprague Dawley SD rats of the same age.
Satellite groups
No treatment-related changes were noted, following histopathology evaluation of bone marrow, spleen and thymus. All reported changes were considered spontaneous and incidental, having a comparable incidence in control and treated groups, and/or are characteristically seen in untreated Sprague Dawley SD rats of the same age.
Tissues which were prepared for microscopic examination and weighed:
Organs / tissues |
Weight |
Fixation / Preservation |
Microscopic examination |
Abnormalities |
- |
Yes |
Yes |
Adrenal glands |
- |
Yes |
Yes |
Bone marrow (from sternum), only satellite groups |
- |
Yes |
Yes |
Brain (cerebrum, cerebellum, medulla/pons) |
- |
Yes |
- |
Clitoral gland |
- |
Yes |
- |
Epididymides |
Yes |
Yes |
Yes |
Kidneys |
- |
Yes |
Yes |
Liver |
- |
Yes |
Yes |
Mammary gland - Females |
- |
Yes |
Yes |
Mammary gland - males |
- |
Yes |
Yes |
Ovaries with oviducts |
Yes |
Yes |
Yes |
Parathyroid glands, weighed and preserved with thyroid gland |
Yes |
Yes |
- |
Pituitary gland |
- |
Yes |
- |
Penis |
- |
Yes |
- |
Prostate gland (dorsolateral and ventral) |
Yes |
Yes |
- |
Sciatic nerve |
- |
Yes |
Yes |
Seminal vesicles with coagulating glands |
Yes |
Yes |
Yes |
Spleen, only satellite groups |
Yes |
Yes |
Yes |
Testes |
Yes |
Yes |
Yes |
Thymus, where present, only in satellite groups |
Yes |
Yes |
Yes |
Thyroid gland |
Yes |
Yes |
Yes |
Uterus – cervix |
Yes |
Yes |
Yes |
vagina |
- |
Yes |
Yes |
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The available key study was conducted according to OECD guideline 421 and is of high quality.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Effects on developmental toxicity
Description of key information
No data for the substance "Sophorolipids: fermentation products of glucose and fatty acids, C18 (unsaturated), glycerol esters with yeast Starmerella bombicola, hydrolysed" on developmental toxicity is available. Therefore, data from a suitable read-across partner was used to assess the developmental toxicity for the target substance. For details and justification of read-across please refer to the report attached in section 13 of IUCLID.
Based on the absence of adverse maternal or fetal effects in an OECD 414 study, a dosage level of 725 mg/kg bw/day (for active ingredient) was considered to be the no‑observed‑adverse‑effect level (NOAEL) for maternal toxicity and embryo/fetal development when the source substance “Sophorolipids: fermentation products of glucose and fatty acids, C18-unsatd., esters with glycerol with yeast Candida bombicola, partially hydrolysed” (solid content: 46.6%) was administered orally by gavage to time-mated Crl:CD(SD) rats. Dose levels have been selected based on information from a previous repeated dose toxicity study (OECD 407) and an OECD 414 DRF study (both Rossiello, 2018).
Link to relevant study records
- Endpoint:
- developmental toxicity
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- For details and justification of read-across please refer to the report attached in section 13 of IUCLID.
- Reason / purpose for cross-reference:
- read-across source
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Test substance-related increased incidences of abnormal breathing sounds were observed in 8 females at approximately 2 hours post-dose in the 725 mg/kg/day group and persisted to the daily examinations in 3 females only during Gestation Days 7–21. These findings were considered non-adverse due to the animals being in otherwise general good health throughout the treatment period. Other clinical observations noted in the test substance-treated groups occurred infrequently, at similar frequencies in the control group, and/or in a manner that was not dose-related.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- Mean maternal body weights, body weight gains, adjusted body weights, adjusted body weight gains in the 72.5, 217.5, and 725 mg/kg/day groups were unaffected by test substance administration. Any statistically significant differences from the control group were transient, did not occur in a dose-responsive manner, and/or did not impact mean absolute body weights.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- In the 725 mg/kg/day group, test substance-related statistically significantly lower mean food consumption was noted during Gestation Days 6–9 compared to the control group. Mean food consumption in this group was comparable to the control group for the remainder of the dosing period (Gestation Days 9–21) and when the entire dosing period (Gestation Days 6–21) was evaluated. There were no corresponding effects on mean body weights or body weight gains, and therefore, the effects on mean food consumption in the 750 mg/kg/day group were considered non-adverse.
Mean food consumption in the 72.5 and 217.5 mg/kg/day were unaffected by test substance administration throughout the study. Differences from the control group were slight and not statistically significant. - Endocrine findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were test substance-related effects on thyroid hormone values (TSH, T3, and T4) at any dose level. Differences from the control group were not statistically significant, observed in a manner that was not dose-related, and were within the ranges of the Historical Control Data.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- Gravid uterine weights in the 72.5, 217.5, and 725 mg/kg/day groups were unaffected by test substance administration.
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 725 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Remarks:
- in terms of test item corrected for solid content (46.6%)
- Remarks on result:
- other: no adverse effects at highest dose
- Key result
- Abnormalities:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Anogenital distance of all rodent fetuses:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test substance-related external malformations were noted in fetuses in this study. A single fetus in the 217.5 mg/kg/day group (No. 3518-09) was observed with proboscis and absent eye bulges, mouth, and lower jaw. These findings were noted in a single mid-dose fetus, and therefore were not considered test substance related. No other external malformations or external developmental variations were observed in fetuses on this study.
- Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Skeletal malformations were noted for 0(0), 1(1), 2(2), and 6(3) fetuses (litters) in the control, 72.5, 217.5, and 725 mg/kg/day groups, respectively; incidences in the test substance-treated groups were not statistically significantly higher than the concurrent control group. In the 725 mg/kg/day group, different types of vertebral malformations were noted in 3 individual litters: Fetus Nos. 4504 05, 4504-16, and 4504-17 were observed with absent lumbar vertebra, Fetus Nos. 4513-01 was observed with an absent rib and thoracic hemivertebra; this fetus was also noted with a lower body weight (3.87 g) compared to the group mean value (5.92 g), and Fetus Nos. 4521-04 and 4521-10 were observed with supernumerary lumbar vertebra. Because the skeletal malformations in the 725 mg/kg/day group were of specific types to fetuses in individual litters, they were considered familial and not related to the test substance administration. In the 217.5 mg/kg/day group, Fetus No. 3503 10 was observed with fused ribs, cervical centrum, cervical arches, and thoracic arches and absent cervical centrum and Fetus No. 3518 09 was noted with multiple malformations in the skull (absent mandible and jugal bones, misshapen nasal, premaxilla, maxilla, squamosal, frontal, parietal, and interparietal bones, small premaxilla, nasal, maxilla, squamosal, tympanic annulus, frontal, parietal, and interparietal bones, large supraoccipital bone, and unossified parietal bone), corresponding to the external malformations noted in this fetus. In the 72.5 mg/kg/day group, Fetus No. 2501-03 was observed with an absent lumbar vertebra. Skeletal malformations in the 50 and 150 mg/kg/day groups were limited to single fetuses, and therefore were not considered test substance related.
Higher incidences (statistically significant) of skeletal developmental variations were noted in the 72.5 and 725 mg/kg/day groups. However, the individual findings were not observed in a dose related manner, the differences in the mean litter proportions were not statistically significant compared to the concurrent control group, and/or the values were within the ranges of the historical control data (version 2017.03). Therefore, the skeletal developmental variations were not considered test substance-related. - Visceral malformations:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 725 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Remarks:
- in terms of test item corrected for solid content (46.6%)
- Sex:
- male/female
- Remarks on result:
- other: no adverse effects at highest dose
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- Based on the absence of adverse maternal or fetal effects, a dosage level of 725 mg/kg/day (for active ingredient) was considered to be the no observed adverse effect level (NOAEL) for maternal toxicity and embryo/fetal development when administered orally by gavage to time-mated Crl:CD(SD) rats.
- Executive summary:
In this developmental toxicity study according to OECD guideline 414 and OPPTS 870.3700, the test substance "Sophorolipids: fermentation products of glucose and fatty acids, C18-unsatd., esters with glycerol with yeast Candida bombicola, partially hydrolysed" (46.6% solid content) was administered to 25 time-mated female Crl:CD(SD) rats/dose at dose levels of 0, 72.5, 217.5 and 725 mg/kg bw/day (based on solid content of 46.6%. Animals were dosed via oral gavage once daily during Gestation Days 6–20. The dose levels were selected based on a LOAEL of 1000 mg/kg bw/day form a GLP-compliant 28 -day study in Sprague Dawley CD rats (Rossiello, 2018) and an OECD 414 DRF study (Rossiello, 2018).
The following parameters and end points were evaluated in this study: clinical signs, body weights, body weight gains, gravid uterine weights, food consumption, thyroid hormone parameters (T3, T4, and TSH), organ weights, macroscopic and microscopic examinations, intrauterine growth and survival, and fetal morphology.
All females survived to the scheduled necropsy on Gestation Day 21. Test substance-related clinical observations noted at the daily examinations or approximately 2 hours postdosing were limited to abnormal breathing sounds in the 725 mg/kg/day group. The animals were otherwise in good health throughout the treatment period, so these effects were not considered adverse.
There were no test substance-related effects on mean maternal body weights, body weight gains, adjusted body weights, adjusted body weight gains, or gravid uterine weights at any dose level.
Test substance-related lower mean maternal food consumption was noted in the 725 mg/kg/day group during Gestation Days 6–9 but was comparable to the control group thereafter. Based on the transient nature of these effects and the lack of corresponding body weight effects, these effects on food consumption were considered non-adverse. No test substance-related effects were observed on food consumption in the 72.5 or 217.5 mg/kg/day groups.
There were no test substance-related effects on maternal thyroid hormone values at any dose level.
There were no test substance-related effects on maternal macroscopic pathology, organ weights, or microscopic evaluations at any dose level.
There were no test substance-related effects on intrauterine growth or survival at any dose level.
There were no test substance-related effects on external, visceral, or skeletal fetal morphology at any dose level.
Based on the absence of adverse maternal or fetal effects, a dosage level of 725 mg/kg/day (for active ingredient) was considered to be the no‑observed‑adverse‑effect level (NOAEL) for maternal toxicity and embryo/fetal development when the test substance "Sophorolipids: fermentation products of glucose and fatty acids, C18-unsatd., esters with glycerol with yeast Candida bombicola, partially hydrolysed" was administered orally by gavage to time-mated Crl:CD(SD) rats.
This information is used in a read-across approach in the assessment of the target substance. For justification of read-across please refer to the attached read-across report (see IUCLID section 13).
Reference
Dose Formulation Analyses
The analyzed dosing formulations contained 92.4% to 101% of the test
substance which was within the protocol-specified range of target
concentrations for solutions (90% to 110%). The test substance was not
detected in the analyzed vehicle formulation that was administered to
the control group (Group 1). Results of the analyses of dosing
formulations are summarized below.
Results of Concentration Analyses (mean concentration, mg/mL % of
target))
- Date of preparation: 2020-11-05. Group 2 (10 mg/mL) 9.49 mg/mL, Group
3 (30 mg/mL) 28.9 mg/mL, Group 4 (100 mg/mL) 95.1 mg/mL.
- Date of preparation: 2020-11-19. Group 2 (10 mg/mL) 9.24 mg/mL, Group
3 (30 mg/mL) 30.4 mg/mL, Group 4 (100 mg/mL) 93.6 mg/mL.
Mortality and Observations
There were no test substance-related effects on survival. All animals
survived to scheduled euthanasia and were gravid.
Test substance-related increased incidences of abnormal breathing sounds
were observed in 8 females at approximately 2 hours postdose in the 725
mg/kg/day group and persisted to the daily examinations in 3 females
only during Gestation Days 7–21. These findings were considered
non-adverse due to the animals being in otherwise general good health
throughout the treatment period. Other clinical observations noted in
the test substance-treated groups occurred infrequently, at similar
frequencies in the control group, and/or in a manner that was not
dose-related.
Body Weights and Gravid Uterine Weights
Mean maternal body weights, body weight gains, adjusted body weights,
adjusted body weight gains, and gravid uterine weights in the 72.5,
217.5, and 725 mg/kg/day groups were unaffected by test substance
administration. Any statistically significant differences from the
control group were transient, did not occur in a dose-responsive manner,
and/or did not impact mean absolute body weights.
Food Consumption
In the 725 mg/kg/day group, test substance-related statistically
significantly lower mean food consumption was noted during Gestation
Days 6–9 compared to the control group. Mean food consumption in this
group was comparable to the control group for the remainder of the
dosing period (Gestation Days 9–21) and when the entire dosing period
(Gestation Days 6–21) was evaluated. There were no corresponding effects
on mean body weights or body weight gains, and therefore, the effects on
mean food consumption in the 750 mg/kg/day group were considered
non-adverse.
Mean food consumption in the 72.5 and 217.5 mg/kg/day were unaffected by
test substance administration throughout the study. Differences from the
control group were slight and not statistically significant.
Thyroid Hormone Analyses
There were test substance-related effects on thyroid hormone values
(TSH, T3, and T4) at any dose level. Differences from the control group
were not statistically significant, observed in a manner that was not
dose-related, and were within the ranges of the Historical Control Data.
Macroscopic Pathology
No test substance-related gross findings were noted. The gross findings
observed were considered incidental, of the nature commonly observed in
this strain and age of rat, and/or were of similar incidence in control
and treated animals and, therefore, were considered unrelated to test
substance administration.
Organ Weights
No test substance-related organ weight changes were noted at any dose
level.
Microscopic Evaluations
No test substance-related microscopic findings in the thyroid gland or
liver were noted. The microscopic findings observed were considered
incidental, of the nature commonly observed in this strain and age of
rats, and/or were of similar incidence and severity in control and
treated animals and, therefore, were considered unrelated to test
substance administration.
Ovarian and Uterine Examinations
Intrauterine growth and survival were unaffected by test substance
administration at dosage levels of 72.5, 217.5, and 725 mg/kg/day.
Parameters evaluated included mean litter proportions of post
implantation loss, mean number of live fetuses, mean fetal body weights,
mean anogenital distance (absolute and relative to cube root of body
weight), and fetal sex ratios. Differences from the control group were
slight, not statistically significant, and/or noted in a manner that was
not dose-related.
Mean numbers of corpora lutea and implantation sites and the mean litter
proportions of pre implantation loss were similar across all groups.
Fetal Morphological Data
The numbers of fetuses (litters) available for morphological evaluation
were 317(25), 318(25), 301(25), and 333(25) in the control, 72.5, 217.5,
and 725 mg/kg/day groups, respectively. Malformations were observed in
0(0), 1(1), 2(2), and 6(3) fetuses (litters) in these same respective
dose groups.
External Malformations and Variations
No test substance-related external malformations were noted in fetuses
in this study. A single fetus in the 217.5 mg/kg/day group (No. 3518-09)
was observed with proboscis and absent eye bulges, mouth, and lower jaw.
These findings were noted in a single mid-dose fetus, and therefore were
not considered test substance related. No other external malformations
or external developmental variations were observed in fetuses on this
study.
Visceral Malformations and Variations
No visceral malformations were noted in fetuses in this study.
No test substance-related visceral developmental variations were noted.
Findings observed in the test substance treated groups were noted
similarly in the control group.
Skeletal Malformations and Variations
Skeletal malformations were noted for 0(0), 1(1), 2(2), and 6(3) fetuses
(litters) in the control, 72.5, 217.5, and 725 mg/kg/day groups,
respectively; incidences in the test substance-treated groups were not
statistically significantly higher than the concurrent control group. In
the 725 mg/kg/day group, different types of vertebral malformations were
noted in 3 individual litters: Fetus Nos. 4504 05, 4504-16, and 4504-17
were observed with absent lumbar vertebra, Fetus Nos. 4513-01 was
observed with an absent rib and thoracic hemivertebra; this fetus was
also noted with a lower body weight (3.87 g) compared to the group mean
value (5.92 g), and Fetus Nos. 4521-04 and 4521-10 were observed with
supernumerary lumbar vertebra. Because the skeletal malformations in the
725 mg/kg/day group were of specific types to fetuses in individual
litters, they were considered familial and not related to the test
substance administration. In the 217.5 mg/kg/day group, Fetus No. 3503
10 was observed with fused ribs, cervical centrum, cervical arches, and
thoracic arches and absent cervical centrum and Fetus No. 3518 09 was
noted with multiple malformations in the skull (absent mandible and
jugal bones, misshapen nasal, premaxilla, maxilla, squamosal, frontal,
parietal, and interparietal bones, small premaxilla, nasal, maxilla,
squamosal, tympanic annulus, frontal, parietal, and interparietal bones,
large supraoccipital bone, and unossified parietal bone), corresponding
to the external malformations noted in this fetus. In the 72.5 mg/kg/day
group, Fetus No. 2501-03 was observed with an absent lumbar vertebra.
Skeletal malformations in the 50 and 150 mg/kg/day groups were limited
to single fetuses, and therefore were not considered test substance
related.
Higher incidences (statistically significant) of skeletal developmental
variations were noted in the 72.5 and 725 mg/kg/day groups. However, the
individual findings were not observed in a dose related manner, the
differences in the mean litter proportions were not statistically
significant compared to the concurrent control group, and/or the values
were within the ranges of the Charles River Ashland historical control
data (version 2017.03). Therefore, the skeletal developmental variations
were not considered test substance-related.
Summary of External, Visceral, and Skeletal Examinations
The numbers of fetuses (litters) available for morphological evaluation
were 317(25), 318(25), 301(25), and 333(25) in the control, 72.5, 217.5,
and 725 mg/kg/day groups, respectively. Malformations were observed in
0(0), 1(1), 2(2), and 6(3) fetuses (litters) in these same respective
dose groups.
When the total malformations and developmental variations were evaluated
on a proportional basis, no statistically significant differences from
the control group were noted, with the following exceptions. The mean
litter proportion of fetuses with any skeletal developmental variations
was statistically significantly higher in the 72.5 and 725 mg/kg/day
groups compared to the control group; when individual developmental
variations were evaluated, only the mean litter proportion of fetuses
with incomplete ossification of the thoracic centrum was statistically
significant in the 72.5 mg/kg/day group. Fetal malformations and
developmental variations, when observed in the test article treated
groups, occurred infrequently or at a frequency similar to that in the
control group, did not occur in a dose-related manner, and/or were
within the historical control data ranges. Based on these data, no fetal
malformations or developmental variations were attributed to the test
article.
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 725 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- The available study is a guideline study and is of high quality.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
The available experimental test data are reliable and suitable for classification purposes under Regulation 1272/2008. No adverse effects on fertility or developmental toxicty were reported. The substance is not considered to be classified for reproductive toxicity under Regulation (EC) No. 1272/2008.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.